The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial chemoembolization (TACE) of dexamethasone application.
HepatoCellular Carcinoma
DRUG: Dexamethasone|DRUG: Normal Saline
response rate (RR), 1 month after TACE|proportions of participants with severe adverse events according to CTCAE v4.03, 1 month after TACE
overall survival (OS), From date of randomization until the date of death from any cause, assessed up to 60 months|progression-free survival (PFS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months|time to progression (TTP), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial chemoembolization (TACE) of dexamethasone application.